Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$0 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-31.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
EV/EBITDA
-3.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-10.1
Face value
--
Shares outstanding
5,234,277
CFO
$-135.77 Mln
EBITDA
$-213.41 Mln
Net Profit
$-123.70 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vincerx Pharma (VINC)
| 4.0 | 2.4 | 4.0 | -97.7 | -91.5 | -87.2 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Vincerx Pharma (VINC)
| -99.8 | -77.5 | 15.7 | -90.0 | -51.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vincerx Pharma (VINC)
|
0.0 | 0.0 | 1.1 | -22.7 | -2,245.8 | -405.3 | -- | 0.0 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform... combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies. It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California. Address: 1825 S. Grant Street, San Mateo, CA, United States, 94402 Read more
Co-Founder, Chairman & CEO
Dr. Ahmed M. Hamdy M.D.
Co-Founder, Chairman & CEO
Dr. Ahmed M. Hamdy M.D.
Headquarters
San Mateo, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Vincerx Pharma Inc (VINC) is $0.01 (NASDAQ) as of 02-Apr-2026 09:30 EDT. Vincerx Pharma Inc (VINC) has given a return of -91.45% in the last 3 years.
Since, TTM earnings of Vincerx Pharma Inc (VINC) is negative, P/E ratio is not available.
The P/B ratio of Vincerx Pharma Inc (VINC) is 0.03 times as on 30-Mar-2026, a 99 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.02
|
0.19
|
|
2023
|
-0.03
|
0.11
|
|
2022
|
-0.02
|
0.02
|
|
2021
|
-0.26
|
0.10
|
|
2020
|
--
|
--
|
The 52-week high and low of Vincerx Pharma Inc (VINC) are Rs 0.69 and Rs 0.00 as of 03-Apr-2026.
Vincerx Pharma Inc (VINC) has a market capitalisation of $ 0 Mln as on 30-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Vincerx Pharma Inc (VINC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.